Blog

rHEALTH’s FVIII Point-of-Care Device Awarded $1.5M Direct-to-Phase II Grant from the NIH

Grant supports efforts to utilize rHEALTH’s point-of-care technology for monitoring FVIII and emicizumab levels in hemophilia A patients BEDFORD, Mass., October 8, 2020 – rHEALTH LLC, a Diagnose Yourself, AnywhereTM company, today announced that its technology is the subject of the award from the National Institute of Health (NIH).  The award is to rHEALTH’s affiliate,...
Read more

rHEALTH Attains ISO 13485 Certification

Certification conforms to worldwide standard for medical device quality and together with the expansion, allows rHEALTH to meet its commercial objectives BEDFORD, Mass., April 22, 2020 – rHEALTH LLC, a Diagnose Yourself, AnywhereTM company, today announced that it has received ISO 13485:2016 certification for the design and development, production and distribution, and servicing of in vitro...
Read more

DMI and COVID-19

Dear Stakeholder, These are challenging times. To me, there is no doubt that humankind will triumph. In doing so, it will show its resiliency, fortitude, and kindness in each of us. As a diagnostic provider, we are currently working with the US federal agencies and our global partner companies to see how our capabilities and expertise may...
Read more

rHEALTH Technology Granted US Patent for Small Volume Blood Handling in Point-of-Care Devices

Invention enables manipulation of small blood samples for accurate point-of-care diagnosis BEDFORD, Mass., January 5, 2020 – rHEALTH LLC, and its affiliate DNA Medicine Institute, Inc., announced today the issuance of United States Patent Number 10,449,537 titled “Capillary manipulation of clinical samples.”  The patent describes a system for collection and delivery of minute blood samples to...
Read more

rHEALTH FVIII Solution to be Presented at WFH’s 11th Global Forum

“We are very pleased to be invited by WFH to present our FVIII solution for home and in-office measurement of FVIII levels.  Our approach provides a high-level of accuracy for FVIII measurements, particularly for long-acting and gene therapy-based FVIII therapies where conventional testing via activated partial thromboplastin time is less appropriate,” said Eugene Y. Chan,...
Read more